Small molecular inhibitors targeting EP300, its paralogue CREBBP, or related proteins of the bromodomain family have consistently shown promising results in leukemia, colorectal cancer, melanoma, and PCa.14, 15, 16. Here, CREBBP is linked to posterior cortical atrophy.